Seattle Genetics moves up FDA timeline for cash cow drug Adcetris

Seattle Genetics will be ready to seek Food and Drug Administration approval for its most important and potentially most lucrative drug sooner than expected, its top executive said. Seattle Genetics has been testing its flagship Adcetris drug as a first line of treatment for patients with advanced lymphoma instead of as a last resort for the cancer, which is currently the drug's only FDA-approved application. CEO Clay Siegall said he expects final results from the Echelon-1 trial in 2017, rather…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news